Categories: PR Newswire

Europe Cell and Gene Therapy Manufacturing QC Market Report 2023-2033: Increasing Demand for Cell and Gene Therapies Spurs Growth

DUBLIN, Feb. 28, 2024 /PRNewswire/ — The “Europe Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033” report has been added to  ResearchAndMarkets.com’s offering.


The Europe cell and gene therapy manufacturing Quality Control (QC) market is expected to reach $2,545.6 million by 2033 from $534.3 million in 2023 at a CAGR of 16.90% during the forecast period 2023-2033.

The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The cell and gene therapy manufacturing Quality Control (QC) market in Europe is experiencing notable growth driven by several factors. With the increasing adoption of cell and gene therapies for treating various diseases, there’s a rising demand for stringent quality control measures to ensure the safety, efficacy, and consistency of these advanced therapies. European regulatory bodies’ emphasis on maintaining high manufacturing standards further propels market expansion.

Additionally, advancements in analytical technologies and automation are enhancing QC processes, facilitating efficient and reliable manufacturing. Furthermore, collaborations between academic institutions, biopharmaceutical companies, and contract manufacturing organizations (CMOs) contribute to the development of innovative QC solutions. As Europe continues to play a leading role in the cell and gene therapy landscape, the QC market is poised for continued growth and innovation.

How can this report add value to an organization?

Workflow/Innovation Strategy:

The Europe cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy:

Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current Europe cell and gene therapy manufacturing QC market.

Competitive Strategy:

Key players in the Europe cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations.

Moreover, a detailed competitive benchmarking of the players operating in the Europe cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Some of the prominent names established in this market are:

  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Lonza.
  • Miltenyi Biotec B.V. & Co. KG
  • Sartorius AG
  • Eurofins Scientific
  • Merck KGaA

Key Topics Covered:

Executive Summary

1 Markets
1.1 Product Definition
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Market Scope
1.2.1 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Cell and Gene Therapy Manufacturing QC Market
1.3.2 Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
1.4 Market Overview
1.4.1 Global Market Scenario
1.4.1.1 Realistic Growth Scenario
1.4.1.2 Optimistic Scenario
1.4.1.3 Pessimistic Scenario
1.4.2 Market Footprint and Growth Potential
1.4.3 Future Potential
1.4.4 COVID-19 Impact on Market
1.4.4.1 Impact on Research and Clinical Operations
1.4.4.2 COVID-19 Impact: Current Scenario of the Market
1.4.4.3 Pre- and Post-COVID-19 Impact Assessment
1.4.4.3.1 Pre-COVID-19 Phase
1.4.4.3.2 Post-COVID-19 Phase

2 Cell and Gene Therapy Manufacturing QC Market: Industry Analysis
2.1 Regulatory Framework
2.1.1 Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
2.1.1.1 Product Testing
2.1.1.2 Microbial Testing
2.1.1.3 Identity
2.1.1.4 Purity
2.1.1.5 Potency
2.1.1.6 Viability
2.1.1.7 Cell Number or Dose
2.1.2 Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
2.1.2.1 Characterization
2.1.2.2 Identity Testing
2.1.2.3 Purity Testing
2.1.3 Current Good Manufacturing Practice (CGMP) Regulations
2.1.3.1 Europe
2.1.4 Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3 Europe
3.1 Overview
3.2 Europe
3.2.1 Europe Cell and Gene Therapy Manufacturing QC Market (by Offering)
3.2.2 Europe Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
3.2.3 Europe Cell and Gene Therapy Manufacturing QC Market (by Process)
3.2.4 Europe Cell and Gene Therapy Manufacturing QC Market (by Technology)
3.2.5 Europe Cell and Gene Therapy Manufacturing QC Market (by Application)
3.3 U.K.
3.4 Germany
3.5 France
3.6 Italy
3.7 Spain
3.8 Rest-of-Europe

4 Company Profiles
4.1 Overview
4.2 Manufacturers
4.2.1 bioMerieux SA
4.2.1.1 Company Overview
4.2.1.2 Role of bioMerieux SA in the Cell and Gene Therapy Manufacturing QC Market
4.2.1.3 Key Competitors
4.2.1.4 Financials
4.2.1.5 Analyst Perspective
4.2.2 F. Hoffmann-La Roche Ltd
4.2.3 Lonza.
4.2.4 Miltenyi Biotec B.V. & Co. KG
4.2.5 Sartorius AG
4.3 Service
4.3.1 Eurofins Scientific
4.3.1.1 Company Overview
4.3.1.2 Role of Eurofins Scientific in the Cell and Gene Therapy Manufacturing QC Market
4.3.1.3 Key Competitors
4.3.1.4 Financials
4.3.1.5 Analyst Perspective
4.3.2 Merck KGaA

For more information about this report visit https://www.researchandmarkets.com/r/uendb9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/europe-cell-and-gene-therapy-manufacturing-qc-market-report-2023-2033-increasing-demand-for-cell-and-gene-therapies-spurs-growth-302074537.html

SOURCE Research and Markets

Dayang Norazhar

Recent Posts

Malaysia Airlines commences gradual reinstatement of flights to and from Sabah, Sarawak and Labuan

MALAYSIA Airlines has commenced the gradual reinstatement of flights to and from Sabah, Sarawak and…

8 mins ago

Bursa Malaysia higher in early trade as investors focus on stocks with high cash reserves

BURSA Malaysia started the morning trading in positive territory, attributed to broad-based buying in response…

16 mins ago

DHGATE Group wins “Best B2B Cross-Border e-commerce Marketplace Company China 2024” at the Global Business & Finance Magazine

BEIJING, April 18, 2024 /PRNewswire/ -- DHGATE Group has won the "Best B2B Cross-Border E-Commerce…

19 mins ago

Ringgit opens easier against US dollar

The ringgit opened easier against the US dollar today as the greenback strengthened further following…

25 mins ago

Vipshop Filed 2023 Annual Report on Form 20-F

GUANGZHOU, China, April 18, 2024 /PRNewswire/ -- Vipshop Holdings Limited (NYSE: VIPS), a leading online…

26 mins ago

Ascott Malaysia’s bold takeover reveals Fox Glenmarie as premier destination

by AKMAR ANNUAR ASCOTT Malaysia, a subsidiary of CapitaLand Investment Ltd, has made a significant…

32 mins ago